A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1213-8. doi: 10.1016/j.bmcl.2011.11.072. Epub 2011 Nov 25.

Abstract

A multivalent approach was applied to the design of long-acting inhaled β(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting β(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C(2)-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection.

MeSH terms

  • Adrenergic beta-2 Receptor Agonists / chemical synthesis
  • Adrenergic beta-2 Receptor Agonists / chemistry
  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Animals
  • Anti-Asthmatic Agents / chemical synthesis
  • Anti-Asthmatic Agents / chemistry
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Cell Line
  • Drug Discovery*
  • Guinea Pigs
  • Humans
  • Molecular Structure
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Stereoisomerism

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Anti-Asthmatic Agents